IP Library Granted Patent US 11,959,135
Granted Patent B2
US 11,959,135 · App. 17/064,633 · Granted Apr 16, 2024

Coupling method

Inventors: James Anthony Clarke (Oxford, GB); James White (Oxford, GB); John Milton (Oxford, GB); Clive Gavin Brown (Cambridge, GB)
Assignee: Oxford Nanopore Technologies PLC
C12Q1/6869B82Y15/00G01N27/44743G01N33/48721
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,959,135
App. No.
17/064,633
Granted
Apr 16, 2024
Kind
B2
Abstract

The invention relates to a new method of determining the presence, absence or characteristics of an analyte. The analyte is coupled to a membrane. The invention also relates to nucleic acid sequencing.

Claims (16)

1. A method for enhancing a target polynucleotide concentration on a surface during nanopore sequencing, the method comprising:

(i) contacting a target polynucleotide construct to a surface comprising a nanopore, and a solid-state membrane supporting a lipid bilayer, wherein the target polynucleotide construct comprises:

(a) a single stranded DNA (ssDNA) leader;

(b) a target polynucleotide; and

(c) one or more reactive groups that interact with the lipid bilayer, under conditions under which the one or more reactive groups interacts with the lipid bilayer and tethers the target polynucleotide construct to the lipid bilayer resulting in enhanced concentration of the target polynucleotide on the surface in proximity to the nanopore; and

(ii) detecting the target polynucleotide using the nanopore.

2. The method according to claim 1 , wherein the target polynucleotide is a DNA polynucleotide or an RNA polynucleotide.

3. The method according to claim 1 , wherein the nanopore is a protein nanopore.

4. The method according to claim 1 , wherein each of the one or more reactive groups comprises a lipid, cholesterol, or fatty acyl chain.

5. The method according to claim 1 , wherein the target polynucleotide construct is tethered to the lipid bilayer at 2, 3, or 4 points.

6. The method according to claim 1 , wherein the ssDNA leader is negatively charged.

7. The method according to claim 6 , wherein the ssDNA leader is positioned 5′ relative to the target polynucleotide.

8. The method according to claim 1 , wherein the target polynucleotide construct is transiently tethered to the lipid bilayer.

9. The method according to claim 1 , wherein the detecting comprises applying an electrical current to the surface such that the tethered target polynucleotide construct moves across the lipid bilayer, thereby increasing interaction of the tethered target polynucleotide construct with the nanopore.

10. The method according to claim 9 , wherein upon application of the electrical current, the ssDNA leader of the tethered target polynucleotide construct is captured by the nanopore.

11. The method according to claim 1 , wherein the detecting comprises measuring current flowing through the nanopore as the target polynucleotide translocates through the nanopore.

Assignments (2)
CHANGE OF NAME Recorded Jan 14, 2022
From: OXFORD NANOPORE TECHNOLOGIES LIMITED
To: OXFORD NANOPORE TECHNOLOGIES PLC
Reel/Frame 058737/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2021
From: CLARKE, JAMES; WHITE, JAMES; MILTON, JOHN; BROWN, CLIVE
To: OXFORD NANOPORE TECHNOLOGIES LIMITED
Reel/Frame 054856/0178 →
Continuity (6)
Continuation 16428845 · May 31, 2019
Continuation 16243118 · Jan 9, 2019
Continuation 14122573
Provisional Application 61599246 · Feb 15, 2012
Provisional Application 61490860 · May 27, 2011
Related Publication 20210095337A1 · Apr 1, 2021
Cited By (2)
US 12,473,595 US 12,571,035